U.S. Clinical Trials Market Size, Share & Trend Report

U.S. Clinical Trials Market Size, Share & Trend Analysis Report By Phase (Phase I, II, III, IV), Study Design (Interventional, Observational), By Indication (Oncology, Diabetes), And Segment Forecasts, 2021 - 2028

  • Published Date: Nov 2021
  • Report ID: GVR-4-68039-580-4
  • Number of Pages: 120
  • Format: Electronic (PDF)
  • Historical Data: 2016 - 2019

Table of Contents

Chapter 1 Methodology and Scope
                   1.1 Market Segmentation & Scope
                        1.1.1 Phase
                        1.1.2 Study Design
                        1.1.3 Indication
                        1.1.4 Estimates And Forecast Timeline
                   1.2 Research Methodology
                   1.3 Information Procurement
                        1.3.1 Purchased Database
                        1.3.2 Gvr’s Internal Database
                        1.3.3 Secondary Sources
                        1.3.4 Primary Research
                        1.3.5 Details Of Primary Research
                   1.4 Information Or Data Analysis
                        1.4.1 Data Analysis Models
                   1.5 Market Formulation & Validation
                   1.6 Model Details
                        1.6.1 Commodity Flow Analysis (Model 1)
                        1.6.2 Volume Price Analysis (Model 2)
                   1.7 List Of Secondary Sources
                   1.8 List Of Primary Sources
                   1.9 List Of Abbreviations
                   1.10 Objectives
                        1.10.1 Objective - 1:
                        1.10.2 Objective - 2:
                        1.10.3 Objective - 3:
                        1.10.4 Objective - 4:
Chapter 2 Executive Summary
                   2.1 Market Outlook
                   2.2 Segment Outlook
                   2.3 Competitive Insights
Chapter 3 Clinical Trials Market: Variables, Trends, & Scope
                   3.1 Market Lineage Outlook
                        3.1.1 Parent market outlook
                        3.1.2 Ancillary market outlook
                   3.2 Penetration & Growth Prospect Mapping
                   3.3 Product Pipeline Analysis, by Stage for COVID-19
                        3.3.1 Therapeutics in development: 271
                        3.3.2 Vaccines in development: 106
                   3.4 Fast track of clinical trials
                        3.4.1 FDA initiative- CTAP
                            3.4.1.1 Accelerating COVID-19 Therapeutic Interventions and Vaccines
                   3.5 Solidarity clinical trial
                        3.5.1 Participation in solidarity trials
                        3.5.2 Solidarity clinical trial for vaccines
                   3.6 Virtual clinical trials
                        3.6.1 In-home clinical services:
                   3.7 COVID-19 pandemic impact on clinical trial activity
                        3.7.1 Disrupted clinical trials:
                        3.7.2 Obstacles in clinical trials:
                   3.8 Market Dynamics
                        3.8.1 Market Driver Analysis
                            3.8.1.1 Adoption of new technology in clinical research
                            3.8.1.2 Shift towards personalized medicine
                            3.8.1.3 Growing disease variation and prevalence
                            3.8.1.4 Increasing collaboration in biomedical research
                            3.8.1.5 Growth in CRO market
                        3.8.2 Market Restraint Analysis
                            3.8.2.1 Pricing pressure
                        3.8.3 Industry Challenges
                            3.8.3.1 Rising cost of clinical trial
                   3.9 U.S. Clinical Trials Market Analysis Tools
                        3.9.1 Porter’s Five Forces Analysis
                        3.9.2 PESTEL Analysis
                        3.9.3 Major Deals & Strategic Alliances Analysis
                            3.9.3.1 Collaboration
                            3.9.3.2 Expansion
                            3.9.3.3 Partnership
                            3.9.3.4 Acquisition
                            3.9.3.5 Product launch
                            3.9.3.6 Merger
                            3.9.3.7 Joint venture
Chapter 4 U.S. Clinical Trials Market: Phase Segment Analysis
                   4.1 U.S. Clinical Trials: Market Share Analysis, 2020 & 2028
                   4.2 Phase I
                        4.2.1 Phase I market, 2016 - 2028 (USD Million)
                   4.3 Phase II
                        4.3.1 Phase II market, 2016 - 2028 (USD Million)
                   4.4 Phase III
                        4.4.1 Phase III market, 2016 - 2028 (USD Million)
                   4.5 Phase IV
                        4.5.1 Phase IV market, 2016 - 2028 (USD Million)
Chapter 5 U.S. Clinical Trials Market: Study Design Segment Analysis
                   5.1 U.S. Clinical Trials: Market Share Analysis, 2020 & 2028
                   5.2 Interventional Studies
                        5.2.1 Interventional market, 2016 - 2028 (USD Million)
                   5.3 Observational Studies
                        5.3.1 Observational studies market, 2016 - 2028 (USD Million)
                   5.4 Expanded Access Studies
                        5.4.1 Expanded access studies market, 2016 - 2028 (USD Million)
Chapter 6 U.S. Clinical Trials Market: Indication Segment Analysis
                   6.1 U.S. Clinical Trials: Market Share Analysis, 2020 & 2028
                   6.2 Autoimmune/Inflammation
                        6.2.1 Autoimmune/inflammation market, 2016 - 2028 (USD Million)
                        6.2.2 Rheumatoid Arthritis
                            6.2.2.1 Rheumatoid arthritis market, 2016 - 2028 (USD Million)
                        6.2.3 Multiple Sclerosis (MS)
                            6.2.3.1 Multiple sclerosis market, 2016 - 2028 (USD Million)
                        6.2.4 Osteoarthritis
                            6.2.4.1 Osteoarthritis market, 2016 - 2028 (USD Million)
                        6.2.5 Irritable Bowel Syndrome (IBS)
                            6.2.5.1 Irritable Bowel Syndrome (IBS) market, 2016 - 2028 (USD Million)
                        6.2.6 Others
                            6.2.6.1 Others market, 2016 - 2028 (USD Million)
                   6.3 Pain Management
                        6.3.1 Pain management market, 2016 - 2028 (USD Million)
                        6.3.2 Chronic pain
                            6.3.2.1 Chronic pain market, 2016 - 2028 (USD Million)
                        6.3.3 Acute pain
                            6.3.3.1 Acute pain market, 2016 - 2028 (USD Million)
                   6.4 Oncology
                        6.4.1 Oncology market, 2016 - 2028 (USD Million)
                        6.4.2 Blood cancer
                            6.4.2.1 Blood cancer market, 2016 - 2028 (USD Million)
                        6.4.3 Solid tumors
                            6.4.3.1 Solid tumors market, 2016 - 2028 (USD Million)
                        6.4.4 Others
                            6.4.4.1 Others market, 2016 - 2028 (USD Million)
                   6.5 CNS Conditions
                        6.5.1 CNS conditions market, 2016 - 2028 (USD Million)
                        6.5.2 Epilepsy
                            6.5.2.1 Epilepsy market, 2016 - 2028 (USD Million)
                        6.5.3 Parkinson's disease (PD)
                            6.5.3.1 Parkinson's disease (PD) market, 2016 - 2028 (USD Million)
                        6.5.4 Huntington's disease
                            6.5.4.1 Huntington's disease market, 2016 - 2028 (USD Million)
                        6.5.5 Stroke
                            6.5.5.1 Stroke market, 2016 - 2028 (USD Million)
                        6.5.6 Traumatic Brain Injury (TBI)
                            6.5.6.1 Traumatic Brain Injury (TBI) market, 2016 - 2028 (USD Million)
                        6.5.7 Amyotrophic Lateral Sclerosis (ALS)
                            6.5.7.1 Amyotrophic Lateral Sclerosis (ALS) market, 2016 - 2028 (USD Million)
                        6.5.8 Muscle Regeneration
                            6.5.8.1 Muscle Regeneration market, 2016 - 2028 (USD Million)
                        6.5.9 Others
                            6.5.9.1 Others market, 2016 - 2028 (USD Million)
                   6.6 Diabetes
                        6.6.1 Diabetes market, 2016 - 2028 (USD Million)
                   6.7 Obesity
                        6.7.1 Obesity market, 2016 - 2028 (USD Million)
                   6.8 Cardiovascular
                        6.8.1 Cardiovascular market, 2016 - 2028 (USD Million)
                   6.9 Other Indications
                        6.9.1 Other indications market, 2016 - 2028 (USD Million)
Chapter 7 U.S. Clinical Trials Indication Outlook, by Study Design, Criss-Cross Analysis
                   7.1 U.S. autoimmune/inflammation clinical trials market, by study design, 2016 - 2028 (USD Million)
                        7.1.1 Interventional studies
                            7.1.1.1 Interventional studies market, 2016 - 2028 (USD Million)
                        7.1.2 Observational Studies
                            7.1.2.1 Observational studies market, 2016 - 2028 (USD Million)
                        7.1.3 Expanded access
                            7.1.3.1 Expanded access market, 2016 - 2028 (USD Million)
                   7.2 U.S. pain management clinical trials market, by study design, 2016 - 2028 (USD Million)
                        7.2.1 Interventional studies
                            7.2.1.1 Interventional studies market, 2016 - 2028 (USD Million)
                        7.2.2 Observational studies
                            7.2.2.1 Observational studies market, 2016 - 2028 (USD Million)
                        7.2.3 Expanded access
                            7.2.3.1 Expanded access market, 2016 - 2028 (USD Million)
                   7.3 U.S. oncology clinical trials market, by study design, 2016 - 2028 (USD Million)
                        7.3.1 Interventional studies
                            7.3.1.1 Interventional studies market, 2016 - 2028 (USD Million)
                        7.3.2 Observational studies
                            7.3.2.1 Observational studies market, 2016 - 2028 (USD Million)
                        7.3.3 Expanded access
                            7.3.3.1 Expanded access market, 2016 - 2028 (USD Million)
                   7.4 U.S. CNS condition clinical trials market, by study design, 2016 - 2028 (USD Million)
                        7.4.1 Interventional studies
                            7.4.1.1 Interventional studies market, 2016 - 2028 (USD Million)
                        7.4.2 Observational studies
                            7.4.2.1 Observational studies market, 2016 - 2028 (USD Million)
                        7.4.3 Expanded access
                            7.4.3.1 Expanded access market, 2016 - 2028 (USD Million)
                   7.5 U.S. diabetes clinical trials market, by study design, 2016 - 2028 (USD Million)
                        7.5.1 Interventional studies
                            7.5.1.1 Interventional studies market, 2016 - 2028 (USD Million)
                        7.5.2 Observational studies
                            7.5.2.1 Observational studies market, 2016 - 2028 (USD Million)
                        7.5.3 Expanded access
                            7.5.3.1 Expanded access market, 2016 - 2028 (USD Million)
                   7.6 U.S. obesity clinical trials market, by study design, 2016 - 2028 (USD Million)
                        7.6.1 Interventional studies
                            7.6.1.1 Interventional studies market, 2016 - 2028 (USD Million)
                        7.6.2 Observational studies
                            7.6.2.1 Observational studies market, 2016 - 2028 (USD Million)
                        7.6.3 Expanded access
                            7.6.3.1 Expanded access market, 2016 - 2028 (USD Million)
                   7.7 U.S. cardiovascular clinical trials market, by study design, 2016 - 2028 (USD Million)
                        7.7.1 Interventional studies
                            7.7.1.1 Interventional studies market, 2016 - 2028 (USD Million)
                        7.7.2 Observational Studies
                            7.7.2.1 Observational studies market, 2016 - 2028 (USD Million)
                        7.7.3 Expanded access
                            7.7.3.1 Expanded access market, 2016 - 2028 (USD Million)
                   7.8 U.S. others clinical trials market, by study design, 2016 - 2028 (USD Million)
                        7.8.1 Interventional studies
                            7.8.1.1 Interventional studies market, 2016 - 2028 (USD Million)
                        7.8.2 Observational Studies
                            7.8.2.1 Observational studies market, 2016 - 2028 (USD Million)
                        7.8.3 Expanded access
                            7.8.3.1 Expanded access market, 2016 - 2028 (USD Million)
Chapter 8 Company Profiles
                   8.1 Company Profiles
                        8.1.1 IQVIA Holdings Inc.
                            8.1.1.1 Company overview
                            8.1.1.2 Financial performance
                            8.1.1.3 Service benchmarking
                            8.1.1.4 Strategic initiatives
                        8.1.2 PAREXEL International Corporation
                            8.1.2.1 Company overview
                            8.1.2.2 Service benchmarking
                            8.1.2.3 Strategic initiatives
                        8.1.3 Pharmaceutical Product Development (PPD)
                            8.1.3.1 Company overview
                            8.1.3.2 Service benchmarking
                            8.1.3.3 Strategic initiatives
                        8.1.4 Charles River Laboratory
                            8.1.4.1 Company overview
                            8.1.4.2 Financial performance
                            8.1.4.3 Service benchmarking
                            8.1.4.4 Strategic initiatives
                        8.1.5 ICON plc
                            8.1.5.1 Company overview
                            8.1.5.2 Financial performance
                            8.1.5.3 Service benchmarking
                            8.1.5.4 Strategic initiatives
                        8.1.6 PRA Health Sciences
                            8.1.6.1 Company overview
                            8.1.6.2 Financial performance
                            8.1.6.3 Service benchmarking
                            8.1.6.4 Strategic initiatives
                        8.1.7 Syneos Health Inc.
                            8.1.7.1 Company overview
                            8.1.7.2 Financial performance
                            8.1.7.3 Service benchmarking
                            8.1.7.4 Strategic initiatives
                        8.1.8 SGS SA
                            8.1.8.1 Company overview
                            8.1.8.2 Financial performance
                            8.1.8.3 Service benchmarking
                            8.1.8.4 Strategic initiatives
                        8.1.9 Wuxi AppTec
                            8.1.9.1 Company overview
                            8.1.9.2 Financial performance
                            8.1.9.3 Service benchmarking
                            8.1.9.4 Strategic initiatives
                        8.1.10 Eli Lilly and Company
                            8.1.10.1 Company overview
                            8.1.10.2 Financial performance
                            8.1.10.3 Service benchmarking
                        8.1.11 Novo Nordisk A/S
                            8.1.11.1 Company overview
                            8.1.11.2 Financial performance
                            8.1.11.3 Service benchmarking
                        8.1.12 Pfizer Inc.
                            8.1.12.1 Company overview
                            8.1.12.2 Financial performance
                            8.1.12.3 Service benchmarking
                            8.1.12.4 Strategic initiatives
                        8.1.13 Covance Inc.
                            8.1.13.1 Company overview
                            8.1.13.2 Financial performance
                            8.1.13.3 Service benchmarking
                            8.1.13.4 Strategic initiatives
                        8.1.14 Clinipace
                            8.1.14.1 Company overview
                            8.1.14.2 Service benchmarking


List of Tables

Table 1 U.S. clinical trials market, by phase, 2016 - 2028 (USD Million)
Table 2 U.S. clinical trials market, by study design, 2016 - 2028 (USD Million)
Table 3 U.S. clinical trials market, by indication, 2016 - 2028 (USD Million)
Table 4 U.S. autoimmune/inflammation clinical trials market, by indication, 2016 - 2028 (USD Million)
Table 5 U.S. pain management clinical trials market, by indication, 2016 - 2028 (USD Million)
Table 6 U.S. oncology clinical trials market, by indication, 2016 - 2028 (USD Million)
Table 7 U.S. CNS conditions clinical trials market, by indication, 2016 - 2028 (USD Million)
Table 8 U.S. autoimmune/inflammation clinical trials market, by study design, 2016 - 2028 (USD Million)
Table 9 U.S. pain management clinical trials market, by study design, 2016 - 2028 (USD Million)
Table 10 U.S. oncology clinical trials market, by study design, 2016 - 2028 (USD Million)
Table 11 U.S. CNS condition clinical trials market, by study design, 2016 - 2028 (USD Million)
Table 12 U.S. diabetes clinical trials market, by study design, 2016 - 2028 (USD Million)
Table 13 U.S. obesity clinical trials market, by study design, 2016 - 2028 (USD Million)
Table 14 U.S. cardiovascular clinical trials market, by study design, 2016 - 2028 (USD Million)
Table 15 U.S. others clinical trials market, by study design, 2016 - 2028 (USD Million)


List of Figures

Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 QFD modeling for market share assessment
Fig. 6 Market formulation & validation
Fig. 7 Commodity flow analysis
Fig. 8 Volume price analysis
Fig. 9 U.S. Clinical trials market snapshot (2020)
Fig. 10 U.S. clinical trials market segmentation
Fig. 11 U.S. clinical trials market: Strategy framework
Fig. 12 Parent market outlook
Fig. 13 Related/ancillary market outlook
Fig. 14 Penetration & growth prospect mapping
Fig. 15 Virtual clinical trials
Fig. 16 Companies with affected trials, by size
Fig. 17 Affected trials, by study phase
Fig. 18 Market driver relevance analysis (Current & future impact)
Fig. 19 Market restraint relevance analysis (Current & future impact)
Fig. 20 Porter’s five forces analysis
Fig. 21 SWOT analysis, by factor (political & legal, economic and technological)
Fig. 22 U.S. clinical trials market phase outlook: Segment dashboard
Fig. 23 U.S. clinical trials market: Phase movement analysis
Fig. 24 Phase I market, 2016 - 2028 (USD Million)
Fig. 25 Phase II market, 2016 - 2028 (USD Million)
Fig. 26 Phase III market, 2016 - 2028 (USD Million)
Fig. 27 Phase IV market, 2016 - 2028 (USD Million)
Fig. 28 U.S. clinical trials market study design outlook: Segment dashboard
Fig. 29 U.S. clinical trials market: Study design movement analysis
Fig. 30 Interventional studies market, 2016 - 2028 (USD Million)
Fig. 31 Observational studies market, 2016 - 2028 (USD Million)
Fig. 32 Expanded access studies market, 2016 - 2028 (USD Million)
Fig. 33 U.S. clinical trials market indication outlook: Segment dashboard
Fig. 34 U.S. clinical trials market: Indication movement analysis
Fig. 35 Autoimmune/inflammation market, 2016 - 2028 (USD Million)
Fig. 36 Rheumatoid arthritis clinical trial by phase (%)
Fig. 37 Rheumatoid arthritis market, 2016 - 2028 (USD Million)
Fig. 38 Multiple sclerosis clinical trial by phase (%)
Fig. 39 Multiple sclerosis market, 2016 - 2028 (USD Million)
Fig. 40 Osteoarthritis clinical trials by phase (%)
Fig. 41 Osteoarthritis market, 2016 - 2028 (USD Million)
Fig. 42 Irritable bowel syndrome clinical trials by phase (%)
Fig. 43 Irritable Bowel Syndrome (IBS) market, 2016 - 2028 (USD Million)
Fig. 44 Others market, 2016 - 2028 (USD Million)
Fig. 45 Pain management market, 2016 - 2028 (USD Million)
Fig. 46 Chronic pain clinical trial by phase (%)
Fig. 47 Chronic pain market, 2016 - 2028 (USD Million)
Fig. 48 Acute pain clinical trial by phase (%)
Fig. 49 Acute pain market, 2016 - 2028 (USD Million)
Fig. 50 Oncology market, 2016 - 2028 (USD Million)
Fig. 51 Blood cancer market, 2016 - 2028 (USD Million)
Fig. 52 Solid tumors market, 2016 - 2028 (USD Million)
Fig. 53 Others market, 2016 - 2028 (USD Million)
Fig. 54 CNS conditions market, 2016 - 2028 (USD Million)
Fig. 55 Epilepsy market, 2016 - 2028 (USD Million)
Fig. 56 Parkinson's disease (PD) market, 2016 - 2028 (USD Million)
Fig. 57 Huntington's disease market, 2016 - 2028 (USD Million)
Fig. 58 Stroke market, 2016 - 2028 (USD Million)
Fig. 59 Traumatic Brain Injury (TBI) market, 2016 - 2028 (USD Million)
Fig. 60 Amyotrophic lateral sclerosis (ALS) market, 2016 - 2028 (USD Million)
Fig. 61 Muscle regeneration market, 2016 - 2028 (USD Million
Fig. 62 Others market, 2016 - 2028 (USD Million)
Fig. 63 Diabetes market, 2016 - 2028 (USD Million)
Fig. 64 Obesity clinical trial by phase (%)
Fig. 65 Obesity market, 2016 - 2028 (USD Million)
Fig. 66 Cardiovascular market, 2016 - 2028 (USD Million)
Fig. 67 Others indications market, 2016 - 2028 (USD Million)
Fig. 68 Interventional studies market, 2016 - 2028 (USD Million)
Fig. 69 Observational studies market, 2016 - 2028 (USD Million)
Fig. 70 Expanded access market, 2016 - 2028 (USD Million)
Fig. 71 Interventional studies market, 2016 - 2028 (USD Million)
Fig. 72 Observational studies market, 2016 - 2028 (USD Million)
Fig. 73 Expanded access market, 2016 - 2028 (USD Million)
Fig. 74 Interventional studies market, 2016 - 2028 (USD Million)
Fig. 75 Observational studies market, 2016 - 2028 (USD Million)
Fig. 76 Expanded access market, 2016 - 2028 (USD Million)
Fig. 77 Interventional studies market, 2016 - 2028 (USD Million)
Fig. 78 Observational studies market, 2016 - 2028 (USD Million)
Fig. 79 Expanded access market, 2016 - 2028 (USD Million)
Fig. 80 Interventional studies market, 2016 - 2028 (USD Million)
Fig. 81 Observational studies market, 2016 - 2028 (USD Million)
Fig. 82 Expanded access market, 2016 - 2028 (USD Million)
Fig. 83 Interventional studies market, 2016 - 2028 (USD Million)
Fig. 84 Observational studies market, 2016 - 2028 (USD Million)
Fig. 85 Expanded access market, 2016 - 2028 (USD Million)
Fig. 86 Interventional studies market, 2016 - 2028 (USD Million)
Fig. 87 Observational studies market, 2016 - 2028 (USD Million)
Fig. 88 Expanded access market, 2016 - 2028 (USD Million)
Fig. 89 Interventional studies market, 2016 - 2028 (USD Million)
Fig. 90 Observational studies market, 2016 - 2028 (USD Million)
Fig. 91 Expanded access market, 2016 - 2028 (USD Million)

 

What questions do you have? Get quick response from our industry experts. Request a Free Consultation
gvr icn

GET A FREE SAMPLE

gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

BBB icon D&B icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.